Five-Year Evaluation of the PROA-NEN Pediatric Antimicrobial Stewardship Program in a Spanish Tertiary Hospital

Aurora Fernández-Polo1, Susana Melendo-Perez2, Nieves Larrosa Escartin3,4

  • 1Pharmacy Department, Hospital Infantil, Institut de Recerca Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

Insights

Implementing a pediatric antimicrobial stewardship program (PROA-NEN) reduced antimicrobial use and costs in pediatric patients. The program improved appropriate antibiotic prescribing without negatively impacting clinical outcomes.

Area of Science:

  • Pediatric Infectious Diseases
  • Antimicrobial Stewardship
  • Public Health

Background:

  • Antimicrobial resistance is a growing threat, especially in pediatric populations with serious infections.
  • Optimizing antimicrobial use is critical to combat resistance and improve patient outcomes.
  • Pediatric antimicrobial stewardship programs (PROA-NEN) are essential for managing infectious diseases.

Purpose of the Study:

  • To evaluate the impact of the PROA-NEN program in a Spanish tertiary hospital.
  • Assess changes in antimicrobial use, prescription quality, clinical indicators, resistance, and costs.
  • Determine the effectiveness of PROA-NEN in a pediatric setting.

Main Methods:

  • Quasi-experimental, single-center study of pediatric patients (0-18 years) from 2015-2019.
  • Assessed process indicators (consumption, prescription quality) and outcome indicators (clinical, microbiological).
  • Utilized quarterly point prevalence analyses for antibiotic prescription quality.

Main Results:

  • Total antimicrobial consumption decreased, particularly in intensive care and surgical units.
  • Appropriate antibiotic prescription rates increased significantly, reaching 83.2%.
  • Direct antimicrobial expenses decreased by 27.3% without compromising clinical outcomes.

Conclusions:

  • The PROA-NEN program effectively reduced antimicrobial consumption and improved appropriate use.
  • The program led to significant cost savings in pediatric antimicrobial therapy.
  • PROA-NEN demonstrated positive results without adverse effects on patient clinical or microbiological outcomes.